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Abstract Atopic dermatitis can result from loss of structural proteins in the outermost epidermal 
layers, leading to a defective epidermal barrier. To test whether this influences tumour formation, 
we chemically induced tumours in EPI−/− mice, which lack three barrier proteins—Envoplakin, 
Periplakin, and Involucrin. EPI−/− mice were highly resistant to developing benign tumours when 
treated with 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate 
(TPA). The DMBA response was normal, but EPI−/− skin exhibited an exaggerated atopic response 
to TPA, characterised by abnormal epidermal differentiation, a complex immune infiltrate and 
elevated serum thymic stromal lymphopoietin (TSLP). The exacerbated TPA response could be 
normalised by blocking TSLP or the immunoreceptor NKG2D but not CD4+ T cells. We conclude 
that atopy is protective against skin cancer in our experimental model and that the mechanism 
involves keratinocytes communicating with cells of the immune system via signalling elements that 
normally protect against environmental assaults.
DOI: 10.7554/eLife.01888.001
Introduction
There is an ongoing debate as to whether allergic disease is a risk factor for cancer or whether it 
is protective, with recent studies indicating that the relationship is complex and site specific (Arana 
et al., 2010; Wedgeworth et al., 2011; Hwang et al., 2012). Several epidemiological studies have 
suggested that atopic dermatitis (AD; eczema), hives, allergies to animal fur, and certain food ingredi-
ents are inversely associated with cancers of tissues that provide an interface with the external envi-
ronment, such as the skin (Jensen-Jarolim et al., 2008; Sherman et al., 2008). In a recent large-scale 
analysis, the risk of nonmelanoma skin cancer was reduced in patients who had both allergic rhinitis 
and asthma (Hwang et al., 2012).
It is challenging to draw firm conclusions from the epidemiological data, in part because of the 
relapsing and remitting nature of AD and the potential cancer modulatory effects of treatments that 
are used to manage AD. Therefore, we sought to examine the link between AD and cancer suscep-
tibility using a mouse model of AD in which the primary defect is in the epidermal barrier that is 
normally protective against pathogens. The skin barrier is formed by terminally differentiated 
keratinocytes in the outermost layers of the epidermis, known as the cornified layers or stratum 
corneum. In cornified keratinocytes, the plasma membrane is replaced with a layer of highly insol-
uble, transglutaminase cross-linked proteins with covalently attached lipids, known as the cornified 
envelope (Candi et al., 2005). Involucrin, envoplakin, and periplakin are the first proteins to be 
cross-linked by transglutaminase-1 and create the protein scaffold for the attachment of lipids on 
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which the cornified envelope assembles (Rice and Green, 1977; Simon and Green, 1984; Ruhrberg 
et al., 1996, 1997).
Mice triply deficient in envoplakin, periplakin, and involucrin (EPI−/− mice) have a defective 
epidermal barrier and exhibit a reduction in epidermal γδTCR+ CD3+ cells (dendritic epidermal 
T cells; DETCs) and infiltration of CD4+ T cells into the dermis (Sevilla et al., 2007). In contrast, the 
individual and double knockouts for envoplakin, periplakin, and involucrin do not have observable 
barrier defects or an altered immune infiltrate (Sevilla et al., 2007). The skin barrier phenotype 
of EPI−/− mice shares similarity with the flaky tail mouse, which has nonsense mutations in the ker-
atin filament associated protein filaggrin and the transmembrane protein Tmem79, which is a 
component of lamellar granules (Fallon et al., 2009; Sasaki et al., 2013; Saunders et al., 2013), 
the latter resulting in defective stratum corneum formation. Filaggrin mutations in humans are 
linked to ichthyosis vulgaris (dry, flaky skin) and increased risk of AD (Palmer et al., 2006, 2007; 
Brown and McLean, 2012), while Tmem79 mutations are found in some patients with AD (Saunders 
et al., 2013).
To test the potential association between a defective skin barrier, AD and cancer, we have 
subjected EPI−/− mice to the classic two-stage chemical carcinogenesis protocol (Perez-Losada 
and Balmain, 2003). A single exposure to the polycyclic aromatic hydrocarbon 7,12-dimethylbenz(a)
anthracene (DMBA) induces oncogenic mutations in HRas (initiation). Repeated applications of 
the promoting agent 12-O-tetradecanoylphorbol-13-acetate (TPA) (promotion) allow initiated, 
mutagenized cells to clonally expand and form benign tumours called papillomas, some of which 
progress to malignant squamous cell carcinomas (SCCs) (Abel et al., 2009). While most human 
skin SCCs are associated with UV, rather than chemical, carcinogenesis, 10% do have Ras gene 
mutations (Lopez-Pajares et al., 2013), and DMBA/TPA carcinogenesis has contributed substan-
tially to our understanding of the steps of tumour development in human skin (Hirst and Balmain, 
2004).
eLife digest Skin cancer is a common and growing problem—according to the World Health 
Organization, skin cancers account for one in every three cancers diagnosed world wide. There is 
some evidence from epidemiological studies that patients with certain allergies might be protected 
against cancer and, in particular, that the allergic skin condition atopic dermatitis is associated with 
reduced levels of various skin cancers. However, it is difficult to know if this reduction is due to the 
atopic dermatitis itself or to the drugs used to treat this allergy.
Genetically engineered mice that are lacking three proteins that are involved in the formation  
of the cornified envelope—the protective layer that replaces the normal plasma membrane in 
the cells of the outermost skin layers—can be used to study atopic dermatitis. These ‘triple 
knockout mice’ have a defective epidermal barrier and altered levels of immune T-cells in  
the skin.
Now Cipolat et al. have investigated whether defects in the epidermal barrier protect against 
skin cancer. Knockout mice and wild-type mice were treated with two chemicals: DMBA, which 
causes mutations in a gene called HRas, and TPA, which promotes the formation of tumours from 
cells that contain HRas mutations. After about 16 weeks almost all of the wild-type mice had at least 
one benign tumour, whereas half of the knockout mice had no tumours. Overall, the average 
number of benign tumours per mouse was six times higher in the wild-type mice. This shows that 
the mutations that cause the epidermal barrier defects in knockout mice also protect them against 
the tumours caused by the combined effects of DMBA and TPA.
Cipolat et al. then compared how the mice responded to DMBA or TPA alone. The knockout 
mice and the wild-type mice responded to DMBA in the same way; however, the knockout mice 
showed an exaggerated response to TPA, including a strong inflammatory reaction. This response 
comprised the production of higher levels of various proteins that are involved in communications 
between skin cells and the immune system. Cipolat et al. propose that the immune reaction caused 
by this exaggerated response could help to prevent tumour formation by eliminating tumour-
forming cells in the skin.
DOI: 10.7554/eLife.01888.002
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Results
EPI −/− mice are resistant to chemical carcinogenesis
To determine whether lack of Evpl, Ppl and Ivl influences sensitivity to tumour formation, we compared 
DMBA/TPA skin carcinogenesis (Abel et al., 2009) in mice lacking all three genes (EPI−/−) and wild-
type (WT) mice on the same genetic background. Since EPI−/− mice were on a mixed Sv129 and 
C57Bl/6 background, F2 crosses between WT Sv129 and C57Bl/6J mice were used to generate the 
WT controls for all experiments. The data from one experiment are presented in Figure 1. A second, 
independent, carcinogenesis experiment gave similar results (data not shown). Mice that received 
DMBA or TPA alone did not develop tumours.
The first papillomas emerged in both groups 5–6 weeks after the start of TPA promotion, and the max-
imum number of papillomas was reached by 15–16 weeks (Figure 1A). The average number of papillomas 
per mouse was approximately sixfold lower in EPI−/− than WT mice (Figure 1A; week 15, p=0.0007; week 
57, p=0.0001). The incidence of papilloma formation was also lower in EPI−/− mice (Figure 1B). Over 95% 
of WT mice had at least one papilloma 14 weeks after the start of promotion, whereas 50% of EPI−/− mice 
were tumour-free at the end of the experiment (p=0.0063). Thus combined deletion of envoplakin, 
periplakin, and involucrin decreased epidermal susceptibility to chemically induced benign tumours.
As expected from the genetic background of the mice (Woodworth et al., 2004), only a small subset 
of papillomas progressed to invasive squamous cell carcinomas (SCCs) (Figure 1C). There was no difference 
in SCC burden or incidence between EPI−/− and WT mice (Figure 1C,D). However, since EPI−/− mice had 
fewer papillomas, the SCC conversion frequency was higher than in WT mice. We observed a downregula-
tion of envoplakin, periplakin, and involucrin in WT papillomas and SCCs (Figure 1E), leading us to speculate 
that the increased risk of SCC conversion in EPI−/− papillomas may be linked to the lack of two desmo-
somal proteins (Thiery and Chopin, 1999). No metastases were observed in any mice (data not shown).
DMBA responsiveness is unaffected in EPI−/− mice
To determine whether the resistance of EPI−/− mice to papilloma formation was due to a reduced 
DMBA response, we examined responses to a single topical application of carcinogen. Skin was ana-
lysed 24 hr after one application of DMBA in 4 mice per genotype.
DMBA binds to the aryl hydrocarbon receptor (AhR), leading to upregulation of the cytochrome 
P-450 enzymes Cyp1a1 and Cyp1b1, which convert DMBA into the active metabolite that causes HRas 
mutations (Gao et al., 2005). There were no differences in expression of AhR, the AhR repressor 
(AhRR), Cyp1a1 and Cyp1b1 between WT and EPI−/− epidermis, either in the steady state or after 
application of DMBA (Figure 2A). Langerhans cells resident in the epidermis metabolise DMBA to the 
active form and as a result DMBA/TPA treated Langerhans cell-deficient mice do not develop papil-
lomas (Modi et al., 2012). However, EPI−/− and WT epidermis contained similar numbers of CD207+ 
Langerhans cells (Figure 2B). We conclude that DMBA was activated to a similar extent whether or not 
the epidermal cornified envelope was defective.
We next analysed epidermal protective responses to carcinogen-induced DNA damage (DNA 
repair and induction of apoptosis). Phosphorylated Histone H2A variant H2AX (γH2AX) is recruited to 
sites of dsDNA damage and subsequent breaks, and is upregulated on DMBA treatment. The propor-
tion of epidermal cells that expressed γH2AX was similar in EPI−/− and WT epidermis, whether or not 
the skin had been treated with DMBA (Figure 2C). The proliferative response of keratinocytes to 
DMBA was comparable in both genotypes, as assessed by the proportion of phospho-Histone 3 (PH3) 
positive cells (Figure 2D). Furthermore, topical application of DMBA resulted in a similar apoptotic 
response, as detected by cleaved caspase-3-positive cells and quantitation of mRNA levels for a panel 
of apoptotic and anti-apoptotic genes (Figure 2E,F).
Levels of the DMBA ‘signature’ Hras (codon 61) mutation (Modi et al., 2012) were the same in 
mRNA extracted from SCCs of WT or EPI−/− mice (Figure 2G). We did not detect mutations in exons 
4, 5, 8 and 9 of p53 in WT or EPI−/− tumours (data not shown).
We conclude that differences in DMBA uptake and activation or activity did not account for the 
resistance of EPI−/− mice to chemical carcinogenesis.
EPI−/− mice exhibit an exacerbated keratinocyte response to TPA
Since WT and EPI−/− mice did not differ in DMBA responsiveness, we next investigated whether 
their response to the promotion phase of the two-stage carcinogenesis protocol was aberrant. Mice 
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Figure 1. Chemical carcinogenesis in EPI−/− and WT mice. (A) Average number of papillomas per mouse. (B) % 
mice with one or more papilloma. (C) Average number of SCCs per mouse. (D) % mice with one or more SCC.  
Figure 1. Continued on next page
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received three topical applications of TPA (or vehicle control), which corresponds to 1 week of pro-
motion, and skin was collected 48 hr after the last treatment.
EPI−/− mice exhibited an exacerbated response to TPA (Figure 3A). Their skin was reddened, dry 
and scaly, whereas that of WT mice was not (data not shown). Histological analysis revealed increased 
hyperkeratosis (thickened stratum corneum) and parakeratosis (retention of nuclei in cornified cells) 
(Figure 3B,C), consistent with defective desquamation (Sevilla et al., 2007). Widening of intercellular 
spaces in the epidermal basal layer (spongiosis) was extensive in EPI−/− but not WT skin (Figure 3A). 
Epidermal thickness, measured as the distance from the basal to the upper granular layer, was greater 
in EPI−/− mice treated with TPA or DMBA/TPA than in WT mice, and this correlated with a greater 
number of suprabasal layers (Figure 3A,D). The numbers of keratinocytes with dsDNA breaks and 
active caspase-3 were similar in EPI−/− and WT epidermis (Figure 3F,G).
The number of mitotically active basal cells, measured by PhosphoHistone3 staining, was similar in 
TPA-treated EPI−/− and WT epidermis, whether or not the skin was pre-treated with DMBA (Figure 3E). 
To examine whether the transit time through the suprabasal layers was altered, mice were injected 
with BrdU 24hr prior to sacrifice and the position of labelled cells was quantified. The numbers of BrdU 
positive cells in the basal layer and outermost granular layers of EPI−/− and WT epidermis were not 
significantly different (Figure 3H). Since EPI−/− epidermis contained more suprabasal layers, the 
transit time of keratinocytes through the epidermis was faster in EPI−/− than WT epidermis. These 
observations are consistent with a model whereby precocious differentiation can act as a tumour sup-
pressive mechanism in skin (Guinea-Viniegra et al., 2012).
(A and C) Data are means ± SEM. (E) Back skin, papillomas (pap) and SCCs from WT mice were immunostained 
for Envoplakin, Periplakin, or Involucrin (red) and DAPI (blue). Dotted line indicates basement membrane. 
Scale bars: 100 μm.
DOI: 10.7554/eLife.01888.003
Figure 1. Continued
Figure 2. Response of EPI−/− and WT mice to DMBA. (A) Q-PCR of enzymes responsible for DMBA uptake and metabolic activation. (B) Number of 
CD207+ Langerhans cells per mm2 ear epidermis. (C–E) Number of epidermal cells that scored positive for γH2AX (C), PH3 (D) or active caspase-3 
(E) per cm. 7-cm skin was analysed per marker. (F) Q-PCR of anti- and pro-apoptotic genes. (A–F) Data in all histograms are means ± SEM of at least 
three mice per genotype. (G) Hras codon 61 mutations in 4 SCCs per genotype were quantified by Q-PCR of genomic DNA.
DOI: 10.7554/eLife.01888.004
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We conclude that, in contrast to the DMBA response, the response of epidermal keratinocytes to 
TPA was markedly different in EPI−/− and WT mice.
EPI−/− mice exhibit an exacerbated inflammatory response to TPA
Because inflammation is a crucial factor in skin tumour development (Johansson et al., 2008; Zamarron 
and Chen, 2011) and EPI−/− skin has an abnormal number of DETCs and CD4+CD3+ lymphocytes 
(Sevilla et al., 2007), we examined whether the inflammatory response to short term TPA treatment 
was altered in skin with a defective epidermal barrier. Consistent with our previous observations 
(Sevilla et al., 2007), vehicle-treated EPI−/− skin had a reduced number of epidermal γδTCR+CD3+ 
lymphocytes (DETCs) (Figure 4A) and EPI−/− γδ T cells exhibited a more rounded morphology, indic-
ative of activation (Figure 4I; Strid et al., 2008). On TPA treatment, the number of DETCs in both 
EPI−/− and WT epidermis decreased (Figure 4A). In contrast, TPA treatment stimulated recruit-
ment of CD4+CD3+ lymphocytes into the skin of EPI−/− mice to a greater extent than in WT mice 
(Figure 4B,J). On TPA treatment, CD4+ T cells infiltrated EPI−/− but not WT epidermis (Figure 4J). 
Infiltration of granulocytes of the neutrophil family (Cd11b+LY6G+) is a typical sign of chronic skin 
inflammation, where they accumulate in pustules (Figure 4D,E). The number of pustules was signifi-
cantly higher in TPA-treated EPI−/− compared with WT skin (Figure 4E).
TPA treated EPI−/− skin showed a pronounced infiltration of dermal mast cells and eosinophils 
(Figure 4F,G), but not macrophages (F4/80+Cd11b+ cells) (Figure 4H). Similar differences in immune 
cell recruitment in EPI−/− and WT skin were observed when mice were treated with DMBA prior to 
TPA (data not shown).
Pustule formation and dermal infiltration of mast cells, eosinophils and CD4+ T cells are hallmarks 
of the acute phase of atopic dermatitis in humans. Thus the response of EPI−/− skin to TPA resembled 
the acute phase of the human disease and involved recruitment of multiple leukocyte subsets.
EPI−/− keratinocytes express elevated levels of cytokines and 
chemokines and an exacerbated lymphoid stress surveillance response
Keratinocytes communicate with different immune cell populations by production of an array of cytokines 
and chemokines, collectively known as the ‘epimmunome’ (Swamy et al., 2010). Tissue damage trig-
gers upregulation of keratinocyte ‘stress-associated’ genes such as Rae-1 (Gasser et al., 2005) and 
H60 (Whang et al., 2009). These stress antigens engage the immunoreceptor NKG2D expressed by 
cells of the innate (NK cells and DETC) and adaptive (activated CD8+ T cells, NKT cells) immune sys-
tem, triggering a lymphoid stress-surveillance response (Hayday, 2009).
To investigate how a defective epidermal barrier could lead to an enhanced inflammatory response 
to TPA, we compared cytokine and chemokine expression in epidermis and dermis of WT and EPI−/− 
mice. We examined markers of innate, type 1 (cellular), type 2 (humoral) and type 17 (anti-microbial) 
immunity. In EPI−/− epidermis treated with acetone, transcripts related to innate immunity (in partic-
ular RAGE, S100A8, S100A9 and IL-1β) were higher than in WT, and these differences were maintained 
when transcript levels were upregulated by TPA treatment (Figure 5A). Type 1 cytokine transcripts 
were expressed at similar levels in WT and EPI−/− epidermis and dermis and were not upregulated to 
the same extent as other types of cytokines by TPA (Figure 5A). There was a striking upregulation of 
type 2 cytokines, including IL-4, IL-6, IL-13, IL-33 and thymic stromal lymphopoietin (TSLP), in epi-
dermis and dermis of EPI−/− TPA-treated mice; this was not observed to a similar extent in WT skin. 
Type 17 transcripts were upregulated by TPA in epidermis of both genotypes, but were higher in 
EPI−/− epidermis (Figure 5A). Increased transcript levels of a number of chemokines, in particular 
Cxcl-5 and GM-CSF, were found in TPA treated EPI−/− vs WT skin, in agreement with the increased 
dermal infiltration of neutrophils and eosinophils. We conclude that the immune response to TPA in 
EPI−/− skin correlated with expression of pro-inflammatory genes with a type 2/type 17 profile.
Consistent with the type 2 response (Figure 5A) and mast cell influx (Figure 4F), serum IgE levels 
were 3.4-fold higher in EPI−/− than WT mice (Figure 5B). There was also a higher level of TSLP in 
EPI−/− serum (Figure 5C). TSLP is mainly produced by keratinocytes and is associated with increased 
resistance to skin carcinogenesis (Kuramoto et al., 2002; Aberg et al., 2008; Demehri et al., 2008, 
2012; Di Piazza et al., 2012). TSLP levels are elevated when Notch signalling in skin is impaired 
(Demehri et al., 2008; Dumortier et al., 2010). However, EPI−/− and WT epidermis expressed com-
parable levels of Notch1, 2 and 3, Notch ligand Jag1 and Notch target genes Hey-1, Hes-1 and Hes-5, 
with or without TPA treatment (Figure 5D). Thus, upregulation of TSLP is associated with barrier 
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Figure 3. Keratinocyte responses to TPA treatment. (A) H&E stained skin sections of mice treated three times with acetone or TPA. Asterisk: neutrophil 
containing pustule; white arrow: spongiosis; black arrow: parakeratosis. % hyperkeratotic (B) and parakeratotic (C) stratum corneum (8 cm skin analysed 
per condition). (D) Epidermal thickness in μm (8 cm skin analysed per condition). (E–G) Number of epidermal cells positively labeled for PH3 (E), γH2AX 
(F) and active caspase-3 (G) per cm skin (7 cm skin analysed per condition). (H) Number of BrdU positive cells in basal and uppermost two granular layers 
per cm epidermis of mice treated three times with TPA and injected with BrdU 24 hr before harvesting. Data from all graphs represent means ± SEM 
from at least four mice per genotype. Scale bar: 100 μm.
DOI: 10.7554/eLife.01888.005
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defects rather than being a direct consequence of altered Notch signalling (Demehri et al., 2008; 
Dumortier et al., 2010).
These results suggested that lymphoid stress-surveillance of tissue damage could underlie the 
exacerbated inflammatory response to TPA exposure in EPI−/− mice. We therefore measured expres-
sion of the keratinocyte ‘stress-associated’ genes Rae-1 and H60 (Figure 5E,F). Rae-1 and H60 levels 
Figure 4. Immune cell responses to TPA treatment. (A–C and E–H) Quantitation of specific T lymphocyte populations (A–C), pustules (E), mast cells (F), 
eosinophils (G), and macrophages (H) per mm epidermis or mm2 dermis. Data in all histograms are means ± SEM of at least three mice per genotype. 
(D, I, J) Skin sections of mice treated three times with acetone (I) or TPA (D and J) and labelled for CD11b (green, D), Ly6G (red, D), CD3 (red I, green J), 
γδTCR (green I) or CD4 (red, J) with DAPI nuclear counterstain (blue). White asterisk: neutrophil pustule. Insets in I and J are higher magnification views 
of boxed areas. Scale bars: 100 μm.
DOI: 10.7554/eLife.01888.006
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Figure 5. Stress signals, cytokine, and chemokine production in EPI−/− and WT skin. (A) Heatmap of mRNA levels 
relative to GAPDH from epidermis and dermis. Each value represents the mean of data obtained from four mice. 
(B and C) Serum levels of IgE (B) and TSLP (C) determined by ELISA. (D–F) Q-PCR of indicated mRNAs in epider-
mis. All histograms represent mean ± SEM (N = 5 untreated, N = 7 acetone, N = 4 DMBA, N = 10 TPA treated mice 
per genotype).
DOI: 10.7554/eLife.01888.007
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were significantly higher in EPI−/− than WT epidermis under steady-state conditions. Both were 
strongly upregulated 24 hr after DMBA treatment, H60 to a greater extent in EPI−/− mice. The effects 
of TPA treatment on Rae-1 and H60 expression were less pronounced. We conclude that the defective 
barrier of EPI−/− mice results in elevated expression of keratinocyte stress-associated genes that 
could prime them for an exacerbated atopic response to TPA.
The TPA response of EPI−/− skin depends on an immune infiltrate, but 
is not specific for neutrophils or CD4+ T cells
To investigate the mechanism by which TPA provoked an exacerbated atopic response in EPI−/− epi-
dermis, we used several different inhibitory strategies. Treatment with the anti-inflammatory drug dexa-
methasone (DXM) markedly reduced epidermal thickening and dermal cellularity (Figure 6A,B). DXM 
also prevented the selective increase in spleen size observed in TPA-treated EPI−/− mice (Figure 6F).
Since tumour resistance of Notch deficient skin is attributable mainly to CD4+ T cells (Demehri 
et al., 2012), we examined the effect of intraperitoneal injections of blocking CD4 antibodies. In vivo 
CD4 depletion was confirmed by quantifying CD4+ cells in the spleen (data not shown). Specific CD4 
targeting resulted in augmented skin hyperplasia and dermal inflammation in TPA-treated WT mice, 
but had no effect on EPI−/− skin (Figure 6C). The immunosuppressive role of CD4+ cells in WT skin 
may be attributable to the regulatory subset of CD4+ cells (CD4+CD25+Foxp3+) (Teige et al., 2009).
There was a marked increase in neutrophil infiltration in EPI−/− TPA-treated skin compared to WT 
(Figure 4D,E). However, when circulating neutrophils were depleted by anti-LY6G injection (Figure 6G), 
there was no effect on epidermal hyperplasia and dermal inflammation (Figure 6D). We also targeted 
IL-4 to evaluate whether inhibition of a generalised type 2 immune response could normalize the 
effects of TPA in EPI−/− skin (Figure 6E). We confirmed a decrease in IL-4 serum levels by ELISA 
(Figure 6H). Inhibition of IL-4 reduced the number of CD4+ cells in the dermis (Figure 6J), as expected, 
but had no effect on epidermal thickness (Figure 6I) nor on the number of mast cells, eosinophils or 
epidermal γδ T cells (data not shown).
Taken together, these observations indicate that the exacerbated TPA response in EPI−/− skin 
involves multiple immune cell types and cannot be normalized by inhibiting one specific leukocyte 
subset.
TSLP and NKG2D inhibition suppress the exacerbated TPA response of 
EPI−/− mice
To analyse the role of the Rae-1/NKG2D/TSLP axis in the exacerbated atopic response of EPI−/− skin 
to TPA, we interfered with the epidermal lymphoid stress surveillance response by in vivo antibody 
blockade of TSLP or NKG2D (Figure 7A). We confirmed effective inhibition of TSLP by ELISA (Figure 7B).
Neutralization of TSLP completely abrogated the atopic dermatitis phenotype in TPA treated 
EPI−/− mice (Figure 7A). Anti-NKG2D also reduced the atopic phenotype, albeit to a lesser extent 
(Figures 7A and 8). TPA-induced epidermal thickening was significantly reduced in TSLP or NKG2D 
suppressive conditions, without any differential effect on the number of PH3+ basal layer cells 
(Figure 7A,C, D). TSLP treatment reduced the transit time of BrdU + cells from the basal to the outer-
most granular layers since although the epidermis was thinner the proportion of labelled granular 
cells was unaffected (Figure 7E,F). There was a slight reduction in hyperkeratosis, and parakeratosis 
was clearly decreased (Figure 7G,H). Targeting the Rae-1/NKG2D/TSLP axis also reduced the number 
of dermal CD4+CD3+ lymphocytes, mast cells, eosinophils, and epidermal pustules in EPI−/− mice 
(Figure 8A–D). Furthermore, under TSLP suppressive conditions the number of epidermal DETCs was 
increased in EPI−/− skin (Figure 8E). Macrophage numbers were unaffected by TSLP or NKG2D block-
ade (data not shown).
To examine whether the anti-inflammatory effects of blocking TSLP were mediated by down-
regulating epidermal expression of inflammatory mediators (Figure 5A), we measured expression of 
representative type 1 and type 2 cytokines. TPA treatment induced a marked and significant release of 
type 2 cytokines (IL-4, IL-6) in the skin and serum of EPI−/− mice, and this was diminished by systemic 
administration of anti-TSLP antibodies (Figure 8F,G). In contrast, there was no effect on the type 1 
cytokines, TNFα and IFNγ. Thus, the inflammation-suppressive effects of systemic TSLP inhibition were 
mediated at the level of both local and systemic suppression of inflammatory mediator production.
EPI−/− SCCs expressed higher TSLP levels than WT SCC (Figure 8I), whereas there were no signif-
icant differences in IL-4 and IL-17 (Figure 8H). In addition, EPI−/− mice bearing papillomas larger than 
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Figure 6. Blocking strategies to revert the atopic response to TPA treatment. (A–E) H&E stained skin sections 
of WT and EPI−/− mice painted with TPA and injected with IgG (A), Dexamethasone (B), α-CD4 antibody  
(C), α-Ly6G antibody (D) or α-IL4 (E). Scale bars: 100 μm. (F) Spleen mass of mice treated with acetone, TPA or 
Figure 6. Continued on next page
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2 mm2 had higher levels of systemic TSLP than EPI−/− mice with smaller papillomas (Figure 8J). This 
indicates that when tumours do arise in an atopic environment, TSLP may have a tumour growth-
promoting role. This is in contrast to the reported ability of TSLP to shrink tumours in Notch-
deficient skin (Demehri et al., 2012), but in agreement with the potent tumorigenic effect of TSLP in 
breast and pancreatic cancers (De Monte et al., 2011; Pedroza-Gonzalez et al., 2011).
We conclude that targeting the Rae1/NKG2D/TSLP axis reverts the atopic phenotype observed 
in EPI−/− mice upon TPA treatment by interfering with the crosstalk between keratinocytes and 
immune cells.
Discussion
Mice deficient in Evpl, Ppl and Ivl exhibited a striking resistance to benign tumour formation. This was 
not due to a difference in DMBA-induced initiation, indicating that the tumour-protective effect was 
not mediated by cell-autonomous changes associated with acquisition of oncogenic mutations. Rather, 
short-term TPA treatment exacerbated atopic dermatitis in EPI−/− mice, resulting in a phenotype that 
shared key hallmarks of the acute phase of the disease in humans (Bieber, 2010) (Figure 9). These 
hallmarks included epidermal acanthosis, spongiosis, hyperkeratosis, and parakeratosis, systemic 
type 2 cell expansion with a dramatic accumulation of CD4+ T cells, neutrophils, eosinophils and 
dermal mast cells, and elevation of serum IgE and TSLP levels.
The enhanced thickening of TPA-treated EPI−/− epidermis reflected an increase in the number of 
suprabasal, differentiated cell layers and defective desquamation. Proliferation in the basal layer was 
similar to wild type, but the transit time of cells through the epidermis was faster. These changes in dif-
ferentiation have previously been shown to be tumour-suppressive in oncogene-driven skin carcino-
genesis (Guinea-Viniegra et al., 2012), consistent with our observation that EPI−/− mice are resistant to 
developing papillomas. Upon TPA treatment EPI−/− defective keratinocytes released high levels of 
chemokines and type 2-type 17 cytokines, including TSLP. This correlated with recruitment of innate 
immune cells, including mast cells, granulocytes (both neutrophils and eosinophils) and adaptive immune 
cells, such as CD4+ T cells, which could potentially play a role in immuno-editing of nascent papillomas.
Defective epidermal differentiation in concert with activation of innate and adaptive immune 
responses is known to create the first line of defence against physical, chemical, and toxic assaults in 
the skin (Milstone, 2004; Sherman et al., 2008). Key players in the crosstalk between keratinocytes 
and leukocytes are DETCs, since they orchestrate the inflammatory response to pathogen-derived and 
environmental signals (King et al., 1999; Moore et al., 2000). DETCs are already in an activated state 
in untreated EPI−/− epidermis, as demonstrated by their round shape and reduced number (Sevilla 
et al., 2007). This is most likely a consequence of increased expression of keratinocyte stress signals 
(Rae-1 and H60), which would be responsible for establishing the observed Th2 immune-surveillance 
response. We propose that this pre-activated, ‘alarmed’ condition enables EPI−/− skin to react more 
promptly and strongly to TPA treatment than WT skin. In contrast to EPI−/− mice, in mice that overex-
press activin βA in the epidermis downregulation of DETCs only occurs after DMBA/TPA treatment and 
is linked to increased skin carcinogenesis (Antsiferova et al., 2011). The exaggerated TPA response 
in EPI−/− mice resulted in increased numbers of CD4+ T cells, neutrophils, mast cells, and eosinophils, 
and many of these leukocyte populations have been shown to be able to exert tumour protective 
effects, which could potentially bypass the function of γδ T cells.
Targeting the Rae-1/NKG2D/TSLP axis, by blocking TSLP or NKG2D, suppressed the crosstalk 
between keratinocytes and immune cells and abrogated the atopic phenotype of TPA-treated EPI−/− 
skin, as seen by normalisation of epidermal differentiation and inflammation. In mice, epidermal 
overexpression of TSLP results in an atopic dermatitis phenotype characterized by epidermal hyper-
proliferation, acanthosis, spongiosis, and hyperkeratosis, as well as mast cell infiltration in the dermis 
(Yoo et al., 2005). In humans, TSLP is implicated in the pathogenesis of both atopic dermatitis and 
TPA + Dexamethasone as % of body weight. Data are means ± SEM from 12 (acetone, TPA) or 3 (TPA + DXM) mice 
per genotype. (G) Numbers of granulocytes per μl blood in TPA treated mice injected with IgG or α-Ly6G antibody. 
(H) Quantification of serum levels of IL-4 in EPI−/− mice treated with IL-4 or control antibodies. (I and J) Effects of 
anti-IL-4 on epidermal thickness (μm) (8 cm skin analysed per condition) (I) and dermal CD4 + T cells (J).
DOI: 10.7554/eLife.01888.008
Figure 6. Continued
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asthma (Leonard, 2002; Al-Shami et al., 2005; Zhou et al., 2005; Huston and Liu, 2006; Liu, 2006). 
TSLP has potent anti-tumour activity in skin carcinogenesis (Demehri et al., 2012; Di Piazza et al., 
2012). Consistent with this, TPA-treated EPI−/− skin produced higher levels of TSLP than WT skin, and 
was protected from chemically induced papilloma formation.
NKG2D ligands have been shown to be upregulated in many inflammatory lesions and can act as 
an axis of immunoregulation (Strid et al., 2008). Our findings demonstrate that the proposed role for 
Rae-1 and NKG2D in establishment of the lymphoid stress-surveillance response and consequent 
atopic phenotype also applies to the situation in which there is a defective epidermal barrier.
Figure 7. TSLP and NKG2D inhibition reduce epidermal responses to TPA. (A) H&E stained sections of skin from TPA-treated mice injected with IgG, 
anti-TSLP, or anti-NKG2D antibodies. (B) Quantification of serum levels of TSLP in WT and EPI−/− mice treated with TSLP or control antibodies. (C and 
D) Quantification of PH3+ cells (C) and epidermal thickness (μm) (D). (E and F) Number of BrdU positive cells in basal (E) and uppermost two granular (F) 
epidermal layers in mice treated with TPA and the indicated antibodies. (G and H) % hyperkeratotic (G) and parakeratotic (H) stratum corneum. (C–D and 
E–F) 7-cm skin analysed per condition.
DOI: 10.7554/eLife.01888.009
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Figure 8. Effects of TSLP and NKG2D inhibition and quantitation of cytokine levels in SCCs. (A–E) CD4+ T cells (A), mast cells (B), eosinophils (C), 
pustules (D), and γδ T cells (E) per mm epidermis or mm2 dermis. Data are means ± SEM from at least three mice per genotype. (F and G) Serum (F) and 
whole skin (G) protein levels of the cytokines indicated. Data are means ± SEM from 6 IgG and 3 α-TSLP-treated mice. (H and I) Q-PCR of mRNAs 
indicated in SCCs. Data are means ± SEM of 4 SCCs per genotype. (J) Serum levels of TSLP in EPI−/− mice bearing papillomas smaller than 2 mm2 or at 
least one papilloma larger than 2 mm2. Data are means ± SEM of at least three mice per group.
DOI: 10.7554/eLife.01888.010
Although two-stage chemical skin carcinogenesis has been used extensively to elucidate the role of 
individual components of the immune system (specific cell types, cytokines and signalling molecules), 
ours is the first mouse model to link the lack of structural proteins and consequent defective epidermal 
barrier to cancer susceptibility. Epidemiological studies of the association between allergic disease 
and cancer risk have given conflicting results, in part because of the difficulty of factoring in immune 
suppressive treatments for the disease and in part because the association can be positive or negative 
according to cancer type (Arana et al., 2010; Van Hemelrijck et al., 2010; Wiemels et al., 2011; 
Jensen et al., 2012; Kaae et al., 2013). Our study provides a mechanistic framework for further 
analysis of the link between atopic dermatitis and cancer incidence.
Materials and methods
EPI−/− and control mice
Mice deficient for envoplakin, periplakin, and involucrin (EPI−/−) were generated as previously 
described (Sevilla et al., 2007) by interbreeding single knockout mice for envoplakin (Maatta et al., 
2001), involucrin (Djian et al., 2000), and periplakin (Aho et al., 2004). Single knockout mice were 
generated and maintained on a variety of genetic backgrounds and as a result there was a potential 
contribution of Sv129, C57BL/6, BALB/c and nu/nu to EPI−/− animals. Since DMBA/TPA sensitivity is 
affected by genetic background (Hennings et al., 1993; Woodworth et al., 2004), DNA of 4 EPI−/− 
mice (each from a different breeding pair) was subjected to genome scanning by the Jackson Laboratory 
(Bar Harbor, ME, USA). Single nucleotide polymorphisms (SNPs) were used to determine the relative 
contributions of different genetic backgrounds. EPI−/− mice were primarily Sv129 (40.98%, ±1.52) and 
C57Bl/6 (51.39%, ±1.62), with a small contribution of BALB/c (4.7%, ±1.24). The nu/nu mutation was 
not detected. Based on these results, the F2 generation of crosses between Sv129 and C57Bl/6J mice 
was used as the WT control (51.82%, ±3.35 Sv129; 49.92%, ±1.98 C57Bl/6) for all experiments.
Two stage carcinogenesis
Chemical carcinogenesis experiments were performed as previously described (Abel et al., 2009). 
All experiments were carried out under the terms of a UK Government Home Office project licence, 
with local ethical approval. The back skin of 7-week-old female mice was shaved with electric clippers. 
3 days later animals that did not show signs of hair regrowth received a topical application of 100 nmol 
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(25 μg) DMBA (Sigma–Aldrich) in 200 μl acetone, followed by three times weekly applications of 
6 nmol (3.7 μg) of TPA (Sigma-Aldrich, Dorset, UK) in 200 μl acetone for 15 weeks. As controls, mice 
(5–10 animals/group) were subjected to the same protocol, but substituting DMBA or TPA with ace-
tone. Papillomas and SCCs were recorded once a week for up to 57 weeks after the start of promotion. 
Recordings were made by an observer who was ‘blinded’ to the experimental groups. 1 hr before 
culling, mice were injected intraperitoneally with 50 mg/kg bodyweight 5-bromo-2'-deoxyuridine 
BrdU (Sigma-Aldrich). In some experiments, age and gender matched mice received 1 application of 
DMBA and/or 3 applications of TPA on alternating days. Skin was harvested 24 hr after DMBA painting 
or 48 hr after the last TPA treatment.
Tissue processing, immunohistochemistry and immunofluorescence 
labelling
For paraffin sections, tissue was fixed in 10% neutral buffered formalin for 24 hr and embedded in 
paraffin after dehydration. For frozen sections, tissue was submerged in OCT embedding matrix 
(Raymond A Lamb, UK) and frozen on dry ice. 4–6 μm (paraffin or frozen) sections were prepared and 
collected onto glass slides.
Quantitation of the proportion of the epidermis with a parakeratotic or hyperkeratotic stratum 
corneum was performed on hematoxylin-eosin stained paraffin sections. A minimum epidermal length 
of 7 cm was analysed from ≥4 mice per condition. Parakeratosis was defined as retention of nuclei in 
the cornified layers. Hyperkeratosis was defined as abnormal thickening of the stratum corneum rela-
tive to wild type, untreated stratum corneum.
BrdU, PH3, and Caspase-3 were detected in formalin-fixed paraffin-embedded sections. Sections 
were dewaxed and rehydrated on an automated Leica ST5020, then treated for antigen-retrieval 
and incubated with primary antibody at the indicated dilution. Secondary antibodies were diluted 
1:250 and probed using the Bond Intense R Detection kit (Leica Microsystems; Wetzlar, Germany). 
Sections were scanned and analysed using the Ariol SL-50 system (Applied Imaging Corp., San Jose).
Figure 9. Model of the role of an epidermal barrier defect in tumour protection. EPI−/− mice lack three cornified 
envelope proteins, resulting in a defective epidermal barrier. Topical application of DMBA induces H-Ras muta-
tions, as in wild-type mice. Topical TPA treatment elicits an exaggerated atopic response, characterized by altered 
keratinocyte differentiation and an enhanced inflammatory response. Epidermal production of TSLP and activation 
of the ligand-NKG2D pathway on immune cells are proposed to contribute to tumour protection.
DOI: 10.7554/eLife.01888.011
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Prior to immunofluorescence staining, frozen sections were air-dried for 10 min at room tem-
perature and fixed in 4% PFA/PBS pH 7.4 for 10 min. Sections were blocked with 2% BSA, 0.02% fish 
skin gelatin, and 10% goat serum for 1 hr in PBS at room temperature. Sections were incubated in 
unconjugated or fluorochrome-conjugated primary antibody and DAPI overnight at 4°C, washed in 
PBS and then mounted using DAKO mounting reagent (DAKO). AlexaFluor 488- or 633-conjugated 
goat anti-rabbit or anti-mouse IgG (Invitrogen) were diluted 1:1000 and used for detection of 
unconjugated primary antibodies. The following species-specific antibodies conjugated with 
Alexafluor 488 or 555 or 647 were used at a dilution of 1:100: anti-CD3 (clone 17.A2; BDPharmingen), 
anti-CD4 (clone RM4-5; eBioscience), anti-CD8α (clone 53-6.7; BioLegend), anti-γδ TCR (clone GL3; 
BDPharmingen), anti-F4/80 (clone BM8; eBioscience), anti-Ly6G (clone 1A8; BDPharmingen), anti-
CD207 (clone eBioRMUL.2; eBioscience) and anti-CD11b (clone M1/70; eBioscience). In-house pro-
duced antibodies against periplakin, envoplakin and involucrin were also used (Ruhrberg et al., 1996, 
1997; Sevilla et al., 2007). The following species-specific unconjugated antibodies were used at the 
dilutions stated: anti-PH3 (Upstate rabbit polyclonal, catalogue number 06-570, 1:500), anti-BrdU 
(Abcam sheep polyclonal, ab1893, 1:500), anti-caspase-3 (Cell Signaling rabbit monoclonal, catalogue 
number 9664, 1:100) and anti-γH2AX (05-636; 1;10; Millipore0). Mast cells were detected with tolui-
dine blue, and eosinophils were detected by Congo red staining.
Hematoxylin and eosin–stained sections of skin and tumours were graded in a blinded manner by 
two experts in mouse skin pathology, as described previously (Owens and Watt, 2001). When quan-
tifying the number of cells that were positive for a particular marker, at least 6 fields per treated skin 
or tumour section were analysed.
Quantitative RT-PCR
RNA was extracted from whole skin, tumours or epidermis that had been scraped from skin following 
heat treatment for 60 s at 56°C in PBS +10 mM EDTA or from cultured keratinocytes using the RNeasy 
mini kit (Qiagen, UK). RNA was quantified using a ND-100 NanoDrop spectrophotometer (NanoDrop 
Technologies). cDNA was prepared using a Superscript III First-Strand Synthesis Supermix for qRT-PCR 
kit (Invitrogen) according to the manufacturers' instructions.
Quantitative RT-PCR was carried out using designed primers and fast SYBR Green or Taqman 
probes with Taqman Fast Universal PCR Master Mix (Applied Biosystems) and run on an ABI Prism 
7900HT Sequence detection system (Applied Biosystems). The RT-PCR was run for 40 cycles and 
specificity of the reactions was determined by subsequent melting curve analysis. Quantitation 
was based on ΔCt calculations using the SDS analysis software and all samples were compared 
against mouse GAPDH as a house keeping control. Matrix visualization was performed using the 
online Matrix2PNG tool (Pavlidis and Noble, 2003). Primers and TaqMan probes are listed in 
Supplementary file 1.
TP53 sequencing and mutant specific HRas qPCR
Genomic DNA was isolated from SCCs using the NucleoSpin kit (Macherey–Nagel) as per the manu-
facturer's protocol. PCR amplification of HRas and p53 exons of interest was performed on 100 ng of 
DNA using primers described previously (Niemann et al., 2007). PCR products were purified and 
sequenced. To quantify the number of DMBA-induced codon-61 Hras CAA->CTA mutations, mutant-
specific primers were used as previously described (Modi et al., 2012). Obtained Ct values were 
normalised against genomic GAPDH (gGAPDH).
Peripheral blood collection, white blood cell analysis, and plasma 
preparation
Mice were anesthetized with Isoflurane (Anaesthesia, UK) and then blood for differential white blood 
cell counts was collected by cardiac puncture in the presence of EDTA (1.75 mg of EDTA dihydrate 
solution per ml of blood) to prevent coagulation. For plasma protein analysis, blood was allowed to 
clot at room temperature for at least 1 hr. After centrifugation at 14,000 rpm for 15 min at 4°C the 
serum was collected, aliquoted, and kept at −80°C until analysis.
Measurement of cytokine production in whole skin and serum
Whole skin lysates and serum were collected, snap-frozen in liquid nitrogen and kept at −80°C prior 
to analysis. The Cytometric Bead Array Cytokine Flex Kit (BD) was used following the manufacturer's 
instructions. Samples were run on a LSR-II flow cytometer and the data were analysed with BD 
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Cytometric Bead Array software. Cytokine production was determined as picograms per ml serum 
or mg of whole skin lysate.
Quantification of ear epidermal Langerhans cells
Epidermal sheets were prepared from mouse ears that had been split into dorsal and ventral sides 
and floated dermal side down for 2 hr at 37°C in 20 mM EDTA. Epidermal sheets were gently lifted 
from the dermis, washed in PBS and fixed in cold acetone for 20 min at −20°C. After washing in PBS, 
epidermal sheets were incubated for 1 hr at room temperature with 2% (g/vol) BSA in PBS and stained 
overnight at 4°C with CD207 Alexa 647 conjugated antibody (eBioscience, clone eBioRMUL.2) and 
DAPI. After extensive washing, epidermal sheets were mounted on slides with DAKO mounting 
medium and visualized by confocal microscopy.
In vivo injection of dexamethasone and inhibitory antibodies
Functional grade purified antibodies against CD4 (16-0042, clone RM4-5 and clone GK1.5, rat IgG2bK; 
eBioscience), TSLP (MAB555, clone 152614; R&D System, 16-5491, clone eBio28F12; eBioscience ), 
NKG2D (catalogue number BE0111; BioXCell), LY6G (clone 1A8; BioXCell), IL-4 (catalogue number 
BE0045; BioXCell), and appropriate isotype controls (BioXCell Rat IgG2a, catalogue number BE0089 
for TSLP and Ly6G; Rat IgG2b, catalogue number BE0090 for CD4; hamster IgG catalogue number 
BE0091 for NKG2D; Rat IgG1, catalogue number BE0088 for IL-4) were injected intraperitoneally at 
a dose of 0.1 mg/mouse. Dexamethasone 21-phosphate disodium salt (DXM) (D1159; Sigma) was 
injected at 10 mg/kg mouse body weight, the same volume of PBS being injected in control mice.
Serum ELISAs
TSLP (Quantikine mouse TSLP kit, R&D Systems), IL-4 (ELISA IL-4 Ready-set-go, eBiosciences), and IgE 
(Bethyl Laboratory) immunoassays were performed on mouse serum according to the manufacturer's 
instructions.
Whole skin lysates
Whole skin protein lysates were prepared by mechanical lysis using ceramic beads (Precellys) in NP-40 
buffer (50 mM Tris–HCl, 150 mM NaCl, 1% NP-40, pH.7.4) with complete protease inhibitor cocktail 
(Roche, Burgess Hill, UK). Tissue was homogenized twice at 1600 rpm for 50 s, then centrifuged for 
20 min 200 µl aliquots were snap frozen and kept at −80C.
Statistics
Statistical analyses were performed using GraphPad Prism (GraphPad Software). The statistical signif-
icance of differences between most experimental groups was determined with a two-tailed Student's 
t-test for unpaired data or Fisher's exact test. For analysis of differences between WT and EPI−/− 
mouse tumour burden Mann Whitney testing was performed. For analysis of differences between WT 
and EPI−/− mouse tumour incidence a test of difference in proportions was used. p-values are indi-
cated with: * 0.01<p<0.05, ** 0.01<p<0.001, *** 0.0001<p<0.001, ****p<0.0001.
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